Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial

cafead

Administrator
Staff member
  • cafead   Jul 05, 2023 at 07:22: PM
via Another FDA accelerated approval has run its course, with Roche giving up on a niche indication for cancer drug Gavreto.

article source